Speciality
Spotlight

 




 


Neonatal & Perinatal


    

 




Respiratory
Disorders

   

  • A Three-Day Course
    of Dexamethasone Therapy to Prevent Chronic Lung
    Disease in Ventilation Neonates: A Randomized Trial

    Garland
    JS, Alex CP, Pauly TH, et al (St. Joseph’s Hosp,
    Milwaukee, Wis; St. Mary’s Hosp, Milwaukee; Univ
    of Kentucky, Lexington; et al)

    Pediatrics
    104: 91-99, 1999


     

    This
    was a randomized placebo controlled study of 241
    neonates, who were assigned to a placebo group (118
    neonates), and a dexamethasone group (123 neonates)
    within 24 to 48 hours of birth. These neonates
    weighed between 500 to 1500 G at birth, had received
    surfactant therapy and were at risk for death by
    chronic lung disease (CLD).

     

    A three-day course of dexamethasone reduced the risk of CLD and also decreased the need for later dexamethasone therapy for these neonates. However there could be an increased risk of intestinal perforation in these neonates receiving early dexamethasone therapy.


      

  • Vitamin
    A Supplementation for Extremely – Low – Birth Weight
    Infants


    Tyson JE, for the National Institute of Child Health
    and Human Development Neonatal Research Network (Univ
    of Texas, Dallas; et al)

    N Engl J Med 340 : 1962-1968, 1999

          

    Extremely – low – birth – weight infants are at risk
    for chronic lung disease and sepsis. Administration
    of vitamin A 5000 IU intramuscularly 3 times a week
    for 4 weeks decreased biochemical evidence of
    vitamin A deficiency and slightly reduced the risk
    of chronic lung disease.

          

    Vitamin A is an essential micronutrient in the
    regeneration of epithelial tissue and also essential
    for septation of the lung and the differentiation of
    alveoli.

        

 



 

 

Speciality Spotlight

 

 

Respiratory Disorders
   

  • A Three-Day Course of Dexamethasone Therapy to Prevent Chronic Lung Disease in Ventilation Neonates: A Randomized Trial
    Garland JS, Alex CP, Pauly TH, et al (St. Joseph’s Hosp, Milwaukee, Wis; St. Mary’s Hosp, Milwaukee; Univ of Kentucky, Lexington; et al)
    Pediatrics 104: 91-99, 1999
     
    This was a randomized placebo controlled study of 241 neonates, who were assigned to a placebo group (118 neonates), and a dexamethasone group (123 neonates) within 24 to 48 hours of birth. These neonates weighed between 500 to 1500 G at birth, had received surfactant therapy and were at risk for death by chronic lung disease (CLD).
     
    A three-day course of dexamethasone reduced the risk of CLD and also decreased the need for later dexamethasone therapy for these neonates. However there could be an increased risk of intestinal perforation in these neonates receiving early dexamethasone therapy.

      

  • Vitamin A Supplementation for Extremely – Low – Birth Weight Infants
    Tyson JE, for the National Institute of Child Health and Human Development Neonatal Research Network (Univ of Texas, Dallas; et al)
    N Engl J Med 340 : 1962-1968, 1999
          
    Extremely – low – birth – weight infants are at risk for chronic lung disease and sepsis. Administration of vitamin A 5000 IU intramuscularly 3 times a week for 4 weeks decreased biochemical evidence of vitamin A deficiency and slightly reduced the risk of chronic lung disease.
          
    Vitamin A is an essential micronutrient in the regeneration of epithelial tissue and also essential for septation of the lung and the differentiation of alveoli.
        

 

 

By |2022-07-20T16:41:54+00:00July 20, 2022|Uncategorized|Comments Off on Respiratory Disorder

About the Author: